Idogen Overview
- Founded
-
2008
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
IDOGEN
- Share Price
-
$0.04
- (As of Friday Closing)
Idogen General Information
Description
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
STO
Primary Office
- Medicon Village
- Scheelevagen 2
- 223 81 Lund
- Sweden
+46 046-275 00 00
Idogen Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.04 | $0.04 | $0.02 - $0.35 | $3.17M | 72.5M | 910K | -$0.17 |
Idogen Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 3,100 | 921 | 3,535 | 749 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (4,259) | (4,359) | (2,765) | (2,833) |
| Net Income | (4,421) | (4,524) | (2,909) | (3,457) |
| Total Assets | 4,970 | 2,549 | 6,198 | 3,336 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Idogen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Idogen Patents
Idogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210299069-A1 | Psammaplin a for modulating ido expression | Pending | 26-Aug-2016 | 0000000000 | |
| EP-3503896-A1 | Psammaplin a for modulating ido expression | Withdrawn | 26-Aug-2016 | 0000000000 | |
| EP-3504326-A1 | Novel use | Withdrawn | 26-Aug-2016 | 0000000000 | |
| US-20190192543-A1 | Novel use | Abandoned | 26-Aug-2016 | 0000000000 | |
| US-20190201431-A1 | Ex vivo methods of inducing ido expression in antigen presenting cells using a compound selected from the group consisting of azacytidine, and decitabine | Abandoned | 26-Aug-2016 | A61K31/7068 |
Idogen Executive Team (14)
Idogen Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 0000000 | Self | Co-Founder, Advisor & Board Member | 000 0000 |
| 000000 Ø000 | Ventac Partners | Board Member | 000 0000 |
Idogen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Idogen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|